ArticleBiomolecules2025
Engineered Fluorescent Variants of Lactadherin C2 Domain for Phosphatidylserine Detection in Flow Cytometry.
Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Phosphatidylserine (PS) is an essential phospholipid and an emerging biomarker involved in key biological processes. While annexin V (axV) is the most widely used tool for PS detection, its calcium-dependent binding and other limitations have spurred interest in alternative probes. The lactadherin C2 domain (lactC2) offers a promising alternative, addressing many of the drawbacks associated with axV. However, its broader adoption has been hindered by challenges in production and modification for convenient experimental use. Here, we demonstrate the successful in-house engineering of fully functional recombinant bovine lactC2-based fluorescent sensors and compare their key parameters to axV probes. We show that mNeonGreen-lactC2 fusion exhibits calcium-independent binding with a comparable dissociation constant for 20% PS liposomes. We also demonstrate the detrimental effects of primary amine modification on lactC2's PS binding efficiency, suggesting the preferential use of fluorescent protein fusion or alternative approaches. Finally, we show that unlike full-length lactadherin or axV, lactC2 inhibited thrombin generation only at high concentrations (>250 nM) in coagulation assays. These findings establish recombinant lactC2 as a versatile and promising PS sensor, with potential applications in experimental settings where axV might be unsuitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.